What is HC Wainwright’s Estimate for MNPR Q1 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for Monopar Therapeutics in a report issued on Thursday, November 12th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.91) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.98) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q2 2027 earnings at ($1.05) EPS, Q3 2027 earnings at ($1.19) EPS and Q4 2027 earnings at ($1.15) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.10.

Several other equities analysts also recently commented on MNPR. UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Morgan Stanley restated an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Finally, BTIG Research reiterated a “buy” rating on shares of Monopar Therapeutics in a report on Thursday. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $122.78.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $72.68 on Friday. Monopar Therapeutics has a twelve month low of $50.07 and a twelve month high of $124.82. The stock’s fifty day simple moving average is $83.52 and its 200 day simple moving average is $77.40.

Insider Activity

In related news, CEO Chandler Robinson sold 29,056 shares of the business’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the transaction, the chief executive officer owned 99,267 shares in the company, valued at $8,735,496. The trade was a 22.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the sale, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. This trade represents a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,920 shares of company stock worth $4,527,913 over the last ninety days. Corporate insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in MNPR. Meeder Asset Management Inc. grew its stake in Monopar Therapeutics by 18.9% during the third quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company’s stock worth $132,000 after purchasing an additional 262 shares during the period. Sei Investments Co. lifted its stake in Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after buying an additional 656 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of Monopar Therapeutics during the 1st quarter worth approximately $250,000. Bank of New York Mellon Corp boosted its holdings in shares of Monopar Therapeutics by 21.2% during the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after buying an additional 13,761 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after buying an additional 30,370 shares in the last quarter. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics News Summary

Investors following MNPR have been watching these news items:

• Positive Sentiment: Cantor Fitzgerald upgraded MNPR from “Neutral” to “Overweight” and set a $119 price target, signaling a more bullish view of the stock. Monopar Therapeutics Stock Moved Up to Overweight by Cantor Fitzgerald
• Positive Sentiment: Monopar reported a third-quarter loss of $0.72 per share, narrower than analysts’ expected loss of $0.82, beating consensus by $0.10. Monopar Reports Third Quarter 2026 Results and Business Updates
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and forecast quarterly losses of $0.91–$1.19 per share for 2027. The continued projected losses temper the positive signals, while the estimates do not indicate a change to its rating.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.